However, because individuals with T2D are resistant to GIP, endogenous GLP-1 may be insufficient for effective glycaemic control, which may partially explain the lower efficacy with DPP-4 inhibitors (12). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.